Literature DB >> 33688718

Influence of Lipophilicity on the Antibacterial Activity of Polymyxin Derivatives and on Their Ability to Act as Potentiators of Rifampicin.

Pamela Brown1,2, Omar Abdulle1, Steven Boakes1, Naomi Divall1, Esther Duperchy1, Sonia Ganeshwaran1, Roy Lester1, Stephen Moss3, Dean Rivers1, Mona Simonovic1, Jaspal Singh1, Steven Stanway3, Antoinette Wilson3, Michael J Dawson1,2.   

Abstract

Novel polymyxin derivatives are often classified either as having direct activity against Gram-negative pathogens or as compounds inactive in their own right, which through permeabilization of the outer membrane act as potentiators of other antibiotics. Here, we report the systematic investigation of the influence of lipophilicity on microbiological activity (including against strains with reduced susceptibility to polymyxins), potentiation of rifampicin, and in vitro toxicity within a series of next-generation polymyxin nonapeptides. We demonstrate that the lipophilicity at the N-terminus and amino acids 6 and 7 in the cyclic peptide core is interchangeable and that the activity, ability to potentiate, and cytotoxicity all appear to be primarily driven by overall lipophilicity. Our work also suggests that the characterization of a polymyxin molecule as either a direct acting compound or a potentiator is more of a continuum that is strongly influenced by lipophilicity rather than as a result of fundamentally different modes-of-action.

Entities:  

Keywords:  Gram-negative; antimicrobial resistance; lipophilicity; multidrug-resistant bacteria; polymyxin; potentiator

Mesh:

Substances:

Year:  2021        PMID: 33688718      PMCID: PMC8138958          DOI: 10.1021/acsinfecdis.0c00917

Source DB:  PubMed          Journal:  ACS Infect Dis        ISSN: 2373-8227            Impact factor:   5.084


  27 in total

1.  A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.

Authors:  Martti Vaara; Osmo Siikanen; Juha Apajalahti; John Fox; Niels Frimodt-Møller; Hui He; Anima Poudyal; Jian Li; Roger L Nation; Timo Vaara
Journal:  Antimicrob Agents Chemother       Date:  2010-05-17       Impact factor: 5.191

Review 2.  Discovery of Novel Polymyxin-Like Antibiotics.

Authors:  Tony Velkov; Kade D Roberts
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

3.  Evaluation of the Rapid Polymyxin NP test and its industrial version for the detection of polymyxin-resistant Enterobacteriaceae.

Authors:  Aurélie Jayol; Nicolas Kieffer; Laurent Poirel; François Guérin; Deniz Güneser; Vincent Cattoir; Patrice Nordmann
Journal:  Diagn Microbiol Infect Dis       Date:  2018-05-16       Impact factor: 2.803

4.  Potentiation of Antibiotic Activity by a Novel Cationic Peptide: Potency and Spectrum of Activity of SPR741.

Authors:  David Corbett; Andrew Wise; Tara Langley; Kirsty Skinner; Emily Trimby; Stephen Birchall; Alain Dorali; Stephanie Sandiford; Jennifer Williams; Peter Warn; Martti Vaara; Troy Lister
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

5.  Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus.

Authors:  Roger L Nation; Jian Li; Otto Cars; William Couet; Michael N Dudley; Keith S Kaye; Johan W Mouton; David L Paterson; Vincent H Tam; Ursula Theuretzbacher; Brian T Tsuji; John D Turnidge
Journal:  Lancet Infect Dis       Date:  2014-10-21       Impact factor: 25.071

6.  Mode of action of the microbial metabolite GE23077, a novel potent and selective inhibitor of bacterial RNA polymerase.

Authors:  Edoardo Sarubbi; Federica Monti; Emiliana Corti; Anna Miele; Enrico Selva
Journal:  Eur J Biochem       Date:  2004-08

7.  Discovery of Dap-3 polymyxin analogues for the treatment of multidrug-resistant Gram-negative nosocomial infections.

Authors:  Thomas V Magee; Matthew F Brown; Jeremy T Starr; David C Ackley; Joseph A Abramite; Jiri Aubrecht; Andrew Butler; Jared L Crandon; Fadia Dib-Hajj; Mark E Flanagan; Karl Granskog; Joel R Hardink; Michael D Huband; Rebecca Irvine; Michael Kuhn; Karen L Leach; Bryan Li; Jian Lin; David R Luke; Shawn H MacVane; Alita A Miller; Sandra McCurdy; James M McKim; David P Nicolau; Thuy-Trinh Nguyen; Mark C Noe; John P O'Donnell; Scott B Seibel; Yue Shen; Antonia F Stepan; Andrew P Tomaras; Paul C Wilga; Li Zhang; Jinfeng Xu; Jinshan Michael Chen
Journal:  J Med Chem       Date:  2013-06-18       Impact factor: 7.446

8.  Interactions of lipopolysaccharide and polymyxin studied by NMR spectroscopy.

Authors:  Jiri Mares; Sowmini Kumaran; Marina Gobbo; Oliver Zerbe
Journal:  J Biol Chem       Date:  2009-02-25       Impact factor: 5.157

9.  Design of Next Generation Polymyxins with Lower Toxicity: The Discovery of SPR206.

Authors:  Pamela Brown; Elizabeth Abbott; Omar Abdulle; Steven Boakes; Scott Coleman; Naomi Divall; Esther Duperchy; Stephen Moss; Dean Rivers; Mona Simonovic; Jaspal Singh; Steven Stanway; Antoinette Wilson; Michael J Dawson
Journal:  ACS Infect Dis       Date:  2019-09-24       Impact factor: 5.084

Review 10.  Polymyxin Derivatives that Sensitize Gram-Negative Bacteria to Other Antibiotics.

Authors:  Martti Vaara
Journal:  Molecules       Date:  2019-01-11       Impact factor: 4.411

View more
  1 in total

Review 1.  Atomic-Resolution Structures and Mode of Action of Clinically Relevant Antimicrobial Peptides.

Authors:  Surajit Bhattacharjya; Sk Abdul Mohid; Anirban Bhunia
Journal:  Int J Mol Sci       Date:  2022-04-20       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.